{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:08:40Z","timestamp":1769918920664,"version":"3.49.0"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006245","name":"Ministry of Science and Technology in Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2410-H-037-002-MY3"],"award-info":[{"award-number":["MOST 111-2410-H-037-002-MY3"]}],"id":[{"id":"10.13039\/501100006245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>From the perspective of health economics, the evaluation of drug-related cost effectiveness and clinical utility is crucial. We conducted a cost\u2013utility analysis of two first-line drugs, tenofovir alafenamide (TAF) and entecavir (ETV), in the treatment of chronic hepatitis B (CHB) patients. We performed inverse probability of treatment weighting (IPTW) to match the independent variables between the two treatment groups. The incremental cost effectiveness ratio (ICER) of the two treatment groups was simulated using a decision tree with the Markov annual-cycle model. A total of 54 patients treated with TAF and 98 with ETV from January 2016 to December 2020 were enrolled. The total medical cost in the TAF group was NT$76,098 less than that in the ETV group, and TAF demonstrated more effectiveness than ETV by 3.19 quality-adjusted life years (QALYs). When the time horizon was set at 30 years, the ICER of the TAF group compared with the ETV group was \u2212NT$23,878 per QALY, suggesting more cost savings for TAF. Additionally, with the application of TAF, over NT$366 million (approximately US$12 million) can be saved annually. TAF demonstrates cheaper medical costs and more favorable clinical QALYs than ETV. To balance health insurance benefits and cost effectiveness, TAF is the optimal treatment for CHB.<\/jats:p>","DOI":"10.3390\/cancers16040813","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T11:50:07Z","timestamp":1708429807000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2013Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0432-3097","authenticated-orcid":false,"given":"Chun-Huang","family":"Lai","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 80457, Taiwan"},{"name":"Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-0190","authenticated-orcid":false,"given":"Hon-Yi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"},{"name":"Department of Business Management, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan"},{"name":"Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan"},{"name":"Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40433, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-En","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 80457, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6579-9922","authenticated-orcid":false,"given":"Yuan-Chieh","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 80457, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Un Frank","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Brown University, Providence, RI 02912, USA"},{"name":"Department of Economics, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, August 01). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_2","unstructured":"Taiwan Ministry of Health and Welfare (2022, August 01). Cause of Death Statistics in Taiwan, Available online: https:\/\/dep.mohw.gov.tw\/DOS\/cp-5069-70304-113.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection: A Review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Oh, H., Lee, H.Y., Kim, J., and Kim, Y.J. (2022). Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers, 14.","DOI":"10.3390\/cancers14112617"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"h4263","DOI":"10.1136\/bmj.h4263","article-title":"Management of chronic hepatitis B infection","volume":"351","author":"Sundaram","year":"2015","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomied, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/jmv.27863","article-title":"Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate","volume":"94","author":"Liang","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Lee, H.W., Lim, T.S., Shin, H.J., Lee, H.W., Kim, S.U., Park, J.Y., Kim, D.Y., Ahn, S.H., and Kim, B.K. (2021). Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers, 13.","DOI":"10.3390\/cancers13235892"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1053\/j.gastro.2019.10.050","article-title":"Challenges with Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B","volume":"158","author":"Liem","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jfma.2012.12.015","article-title":"Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan","volume":"112","author":"Lee","year":"2013","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_14","first-page":"8674038","article-title":"Content-Based Image Retrieval Using Gamma Distribution and Mixture Model","volume":"8674038","author":"Khan","year":"2022","journal-title":"J. Funct. Space"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chiang, C.L., Chan, S.K., Lee, S.F., and Choi, H.C. (2021). First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 13.","DOI":"10.3390\/cancers13050931"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3758\/s13428-022-01837-0","article-title":"Non-parametric mixture modeling of cognitive psychological data: A new method to disentangle hidden strategies","volume":"55","author":"Archambeau","year":"2023","journal-title":"Behav. Res. Methods"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26934","article-title":"Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China","volume":"60","author":"Toy","year":"2014","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s12072-021-10262-y","article-title":"Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients","volume":"15","author":"Chon","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_20","first-page":"3882","article-title":"Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan\u2014A retrospective study","volume":"10","author":"Chen","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/JHC.S330301","article-title":"Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia","volume":"8","author":"Wang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","article-title":"Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"300.e1","DOI":"10.1016\/j.cmi.2021.06.024","article-title":"Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China","volume":"28","author":"Dai","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.apsb.2021.03.028","article-title":"Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment","volume":"11","author":"Xie","year":"2021","journal-title":"Acta. Pharm. Sin. B"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/hep4.1964","article-title":"First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide","volume":"6","author":"Pan","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MEG.0000000000001733","article-title":"Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels","volume":"32","author":"Kumada","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, J., Hu, C., Chen, Y., Zhang, R., Fu, S., Zhou, M., Gao, Z., Fu, M., Yan, T., and Yang, Y. (2021). Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06237-x"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B","volume":"42","author":"Jung","year":"2022","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jval.2015.05.007","article-title":"Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom","volume":"18","author":"Bermingham","year":"2015","journal-title":"Value Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s12072-016-9741-6","article-title":"Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China","volume":"10","author":"Ke","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/CM9.0000000000000445","article-title":"First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China","volume":"132","author":"Yin","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_33","first-page":"335","article-title":"Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis","volume":"9","author":"Ma","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: A systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_35","unstructured":"Taiwan Ministry of the Interior (2023, February 01). Population of Taiwan, Available online: https:\/\/www.moi.gov.tw\/english\/cl.aspx?n=7872."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:01:04Z","timestamp":1760104864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040813"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040813","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]}}}